Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday

Key Points

• Cardiol Therapeutics is set to report its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.11) per share.
• The stock traded down 0.4% to $1.38, with a 12-month low of $0.77 and a high of $2.63.
• HC Wainwright has issued a "buy" rating for Cardiol Therapeutics, setting a price target of $9.00 for the stock.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Cardiol Therapeutics Stock Performance

NASDAQ:CRDL traded down $0.09 during midday trading on Friday, hitting $0.99. The company's stock had a trading volume of 1,651,672 shares, compared to its average volume of 725,801. Cardiol Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.63. The firm's 50 day moving average is $1.36 and its 200-day moving average is $1.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.26 and a quick ratio of 3.26. The firm has a market cap of $81.51 million, a P/E ratio of -2.90 and a beta of 1.05.

Wall Street Analyst Weigh In

Separately, HC Wainwright initiated coverage on shares of Cardiol Therapeutics in a report on Monday, June 2nd. They issued a "buy" rating and a $9.00 price target on the stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.